We investigated the anticancer effect of the aptamerâconjugated gemcitabineâloaded atelocollagen patch in a pancreatic cancer patientâderived xenograft (PDX) model to propose a future potential adjuvant surgical strategy during curative pancreatic resection for pancreatic cancer. A pancreatic cancer PDX model was established. Animals were grouped randomly into a noâtreatment control group; treatment group treated with intraperitoneal gemcitabine injection (IPâGEM) or aptamerâconjugated gemcitabine (APT:GEM); and transplant with three kinds of patches: atelocollagenâaptamerâgemcitabine (patch I), atelocollagenâinactive aptamerâgemcitabine (patch II), and atelocollagenâgemcitabine (patch III). Tumor volumes and response were evaluated based on histological analysis by H&E staining and Immunohistochemistry (IHC) was performed. Anticancer therapyârelated toxicity was evaluated by hematologic findings. The patch I group showed the most significant reduction of tumor growth rate, compared with the noâtreatment group (p < 0.05). However, other treatment groups were not found to show significant reduction in tumor growth rate (0.05 < p < 0.1). There was no microscopic evidence suggesting potential toxicity, such as inflammation, nor necrotic changes in liver, lung, kidney, and spleen tissue. In addition, no leukopenia, anemia, or neutropenia was observed in the patch I group. This implantable aptamerâdrug conjugate system is thought to be a new surgical strategy to augment the oncologic significance of marginânegative resection in treating pancreatic cancer in near future.